Snapshot Highlights
- Expert in Medical Oncology with extensive experience.
- Distinguished publication record in peer-reviewed journals.
- Affiliated with Acıbadem Health Group, a leading healthcare provider.
- Holds board certifications from prestigious institutions.
Dr. LEYLA OZER
Professional Journey
Dr. Leyla Ozer brings a wealth of experience in Medical Oncology, dedicating her career to advancing patient care and treatment strategies. Her professional path showcases a commitment to continuous learning and application of the latest medical knowledge.
Education and Training
Dr. Ozer’s foundational medical education was completed at Istanbul University Cerrahpasa Medical Faculty in 2001. She further honed her expertise through specialized training in Internal Medicine at Istanbul University Istanbul Faculty of Medicine, graduating in 2008. Her advanced specialization in Medical Oncology was also achieved at Istanbul University Istanbul Faculty of Medicine in 2013, establishing her as a highly qualified oncologist.
Clinical Experience
Since 2015, Dr. Ozer has been a valued member of the Acıbadem Health Group, contributing her extensive knowledge and skills to patient care. Prior to this, she served at Fırat University Hospital, Department of Medical Oncology, from 2014 to 2015, where she further developed her clinical acumen in oncology.
Professional Affiliations and Contributions
Dr. Ozer is an active participant in the medical community, holding membership in the esteemed Turkish Medical Oncology Association. Her scholarly contributions are evident through a significant list of publications in the field of oncology, demonstrating her engagement with scientific research and her commitment to sharing vital findings that can impact patient outcomes and future medical advancements. These publications cover a range of critical topics, from gene therapy applications and treatment outcomes for specific cancers like Kaposi sarcoma and triple-negative breast cancer, to diagnostic markers and the prevalence of hyponatremia in oncology patients. Her research also extends to the prognostic factors in metastatic pancreatic cancer and rare presentations of hematologic malignancies.